Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TetraFHER2-vcMMAE: sourced facts only. name: "To exploit the pro-endocytic potential of developed proteins, we constructed the tetravalent fluorescent cytotoxic conjugate TetraFHER2-vcMMAE and demonstrated its high potency and selectivity against HER2+ breast cancer cells." [PMID:40581863]; target: "To exploit the pro-endocytic potential of developed proteins, we constructed the tetravalent fluorescent cytotoxic conjugate TetraFHER2-vcMMAE and demonstrated its high potency and selectivity against HER2+ breast cancer cells." [PMID:40581863]; developer: "Department of Medical Biotechnology, Faculty of Biotechnology, University of Wroclaw, F. Joliot-Curie 14a, 50-383 Wroclaw, Poland." [PMID:40581863]; stage: "we constructed the tetravalent fluorescent cytotoxic conjugate TetraFHER2-vcMMAE and demonstrated its high potency and selectivity against HER2+ breast cancer cells." [PMID:40581863]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TetraFHER2-vcMMAE.